Home / Resources / News / Faye Woolf Talks to PharmaVoice about COVID-19’s Positive Impact on the Clinical Trial Industry

The Aperio Blog

Home / Resources / News / Faye Woolf Talks to PharmaVoice about COVID-19’s Positive Impact on the Clinical Trial Industry

Faye Woolf Talks to PharmaVoice about COVID-19’s Positive Impact on the Clinical Trial Industry

February 2, 2021

COVID-19 Positive Impact on Clinical TrialsCheck-out PharmaVoice’s February edition of Commanders & Chiefs to see what Aperio’s Founder and CEO Faye Woolf had to say about getting back to the business of clinical trials and how COVID-19 forced the industry to adapt and adopt some much needed changes.

Read here.

About Aperio Clinical Outcomes

Aperio Clinical Outcomes provides full, customizable clinical research services across multiple therapeutic areas. Dedicated to transparent interactions with clients, Aperio also offers consulting services in Quality Assurance, Strategic Resourcing, and practical application of the latest Clinical Trial Technology.

In an industry flooded with data, metrics and technology, Aperio remains steadfastly focused on the most important part of the process: people. From start-up to close out and every point in between, Aperio works with its partners to deliver outcomes that will improve patient care and save lives.

Aperio Clinical Outcomes.
We make it clear.

Share this...

Learn how Aperio Clinical Outcomes can help you.
Contact us today.